Ipsen Pharma SA

What Ipsen Pharma SA does

Ipsen Pharma SA is a France-headquartered (Boulogne-Billancourt) global biopharmaceutical company listed on Euronext Paris (ticker: IPN) that develops and commercializes prescription medicines across three focused therapeutic areas: Oncology, Rare Disease, and Neuroscience. The company's marketed portfolio includes Dysport (botulinum toxin for spasticity, cervical dystonia, and aesthetics, with 30+ years of neuroscience expertise), the Cabozantinib franchise (tyrosine kinase inhibitor for renal cell carcinoma and other tumors), Bylvay/odevixibat (ileal bile acid transport inhibitor for progressive familial intrahepatic cholestasis), IQIRVO/elafibranor (PPAR agonist for primary biliary cholangitis), and Ojemda/tovorafenib (BRAF inhibitor for pediatric low-grade glioma, EU-approved in April 2026). Pipeline assets include corabotase, a first-in-class recombinant neuroinhibitor unveiled in 2026, and IPN60340 in acute myeloid leukemia acquired via ImCheck Therapeutics.

Ipsen generates revenue through global commercialization of these prescription medicines, primarily via direct field sales to specialist physicians, hospitals, and specialty pharmacies, supplemented by regional distribution partners in markets without direct presence. FY2025 total sales reached €3.67 billion, growing 10.9% at constant exchange rates with a 35.2% core operating margin and €754 million invested in R&D. The company operates commercial infrastructure in over 30 countries and maintains a manufacturing site at Signes, France, awarded two Shingo Gold prizes for operational excellence.

The business model centers on high-unmet-need patient populations across cancer, rare liver and neurogenetic diseases, and neurological conditions, with Ipsen holding 17% market share in the $2.87 billion global neuroendocrine tumors treatment market. Capital allocation is characterized by active M&A — ImCheck (2025), Memo Therapeutics AG (announced 2026), and Kartos Therapeutics (announced 2026) — supplemented by partnerships with academic institutions and patient organizations. The company employs over 5,000 people globally, is led by CEO David Loew, and reports full gender parity on its Executive Leadership Team.

Name

Ipsen Pharma SA

Legal name

Ipsen Pharma SAS

Website

https://ipsen.com

Company type

Public

Founded year

1983

Operating status

Operating

Short description

Ipsen Pharma SA is a France-headquartered global biopharmaceutical company that develops and commercializes prescription medicines across oncology, rare disease, and neuroscience, serving specialist physicians, hospitals, and patients in over 30 countries. FY2025 sales reached €3.67 billion.

Ownership category

akta.pro rank

Product category

Specialty Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Specialty biopharmaceuticals
• Oncology therapeutics
• Rare disease treatments
• Neuroscience medicines
• Prescription pharmaceuticals

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices26 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Ipsen generates revenue through the global commercialization of prescription medicines across three therapeutic areas: Oncology, Rare Disease, and Neuroscience. Revenue grew 10.9% at constant exchange rates in 2025, with total sales of €3.67 billion.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Ipsen Pharma SA develops, manufactures, and commercializes specialty prescription biopharmaceuticals across three therapeutic franchises: Oncology (treatments for neuroendocrine tumors, renal cell carcinoma, pediatric low-grade glioma, and other cancers), Rare Disease (treatments for progressive familial intrahepatic cholestasis, biliary atresia, and primary biliary cholangitis), and Neuroscience (Dysport® botulinum toxin for spasticity, cervical dystonia, and medical aesthetics). Its portfolio includes marketed drugs Dysport®, Bylvay®, IQIRVO®, Ojemda®, and the Cabozantinib franchise, supported by an R&D pipeline including corabotase and IPN60340.

Product overview

Ipsen Pharma SA is a biopharmaceutical company operating across three therapeutic areas: Oncology, Rare Disease, and Neuroscience. The company's product portfolio includes marketed medicines such as Dysport® (botulinum toxin for spasticity and aesthetics), Bylvay® (odevixibat for progressive familial intrahepatic cholestasis), IQIRVO® (for primary biliary cholangitis), Ojemda® (tovorafenib for pediatric low-grade glioma), and the Cabozantinib franchise (for renal cell carcinoma). The pipeline includes corabotase, a first-in-class recombinant neuroinhibitor for aesthetic applications, and IPN60340 for acute myeloid leukemia. Ipsen focuses on areas of high unmet medical need, developing treatments for complex tumors, rare liver diseases, and neurological conditions including spasticity.

Differentiator

Problem solved

Functional benefit

Products and services

• Dysport® (abobotulinumtoxinA) Botulinum toxin type A product used to treat adult and pediatric upper limb spasticity, cervical dystonia, and medical aesthetic conditions such as glabellar lines, supported by over 30 years of neuroscience expertise.
• Bylvay® (odevixibat) Ileal bile acid transport inhibitor approved for progressive familial intrahepatic cholestasis (PFIC) and in development for biliary atresia, addressing rare pediatric cholestatic liver diseases.
• IQIRVO® (elafibranor) PPAR agonist approved for the treatment of primary biliary cholangitis, with clinical evidence of impact on alkaline phosphatase (ALP) reduction, fatigue, and pruritus.
• Ojemda® (tovorafenib) BRAF inhibitor approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration, addressing a high unmet need in pediatric oncology.
• Cabozantinib franchise Tyrosine kinase inhibitor franchise used in the treatment of renal cell carcinoma and other solid tumors, forming a core component of Ipsen's oncology commercial portfolio.
• Neuroendocrine Tumors Portfolio Marketed oncology treatments for neuroendocrine tumors (NETs), kidney cancer, liver cancer, pancreatic cancer, thyroid cancer, prostate cancer, breast cancer, and acute myeloid leukemia, holding a 17% share of the global NET treatment market valued at USD 2.87 billion in 2025.
• corabotase (RNI™) First-in-class recombinant neuroinhibitor in development for medical aesthetic applications including glabellar lines, with Phase II data demonstrating a differentiated long-acting clinical profile.
• IPN60340 Lead clinical-stage oncology program for acute myeloid leukemia (AML) acquired through the ImCheck Therapeutics acquisition, part of Ipsen's expanding hemato-oncology pipeline.

Quantifiable outcome

• Total sales of €3.67 billion in 2025, growing 10.9% at constant exchange rates
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Memo Therapeutics AGcoreStrategic or Co-development Partner · 1 July 2026Ipsen to acquire Memo Therapeutics AG, adding a first-in-class BK polyomavirus antibody to expand its rare disease portfolio. This acquisition strengthens Ipsen's rare disease pipeline with an innovative antibody candidate.
• Kartos TherapeuticscoreStrategic or Co-development Partner · 29 June 2026Ipsen to acquire Kartos Therapeutics, expanding its hemato-oncology late-stage pipeline. This acquisition adds to Ipsen's growing oncology franchise and complements its existing hematology programs.
• ImCheck TherapeuticscoreStrategic or Co-development Partner · 1 January 2025Ipsen's acquisition of ImCheck Therapeutics expanded its Oncology pipeline with the addition of the lead clinical-stage program IPN60340 in acute myeloid leukemia (AML).
• IRICoR / Institut de recherche en immunologie et en cancérologie, Université de MontréalcoreStrategic or Co-development PartnerLong-standing partnership between Ipsen and IRICoR at Université de Montréal serves as a model of cooperation between academia and industry to accelerate targeted science. The collaboration has been ongoing for multiple years.
• World Stroke OrganizationminorGTM or Marketing PartnerIpsen collaborated with the World Stroke Organization to create the 'Neuro Connections' podcast series, bringing together specialists, patient association representatives, and healthcare professionals from around the world to address current challenges in post-stroke care.
• PFIC NetworkminorGTM or Marketing PartnerPatient organization partnership for Progressive Familial Intrahepatic Cholestasis (PFIC) awareness. Ipsen developed 'PFIC Colors' initiative to help families understand PFIC conditions and find information and support.
• Alagille Syndrome AllianceminorGTM or Marketing PartnerPatient organization partnership supporting awareness and support for patients with Alagille syndrome. Ipsen participates in Alagille Syndrome Awareness Day alongside the alliance.
• PBC FoundationminorGTM or Marketing PartnerPatient organization partnership for Primary Biliary Cholangitis (PBC) awareness. Ipsen developed the 'This is My PBC' awareness initiative and collaborates with the PBC Foundation to provide support and resources.
• Fondation IpsencoreOthersEstablished in 1983 under the aegis of the Fondation de France, Fondation Ipsen leads social and educational projects that raise awareness of rare disease. Its mission is to ensure that all people living with rare disease are treated with respect and receive an accurate and timely diagnosis. Part of Ipsen's founding Beaufour family's nearly 100-year legacy.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Galderma: Swiss-headquartered specialty pharmaceutical company with a leading aesthetics and dermatology portfolio. Directly comparable in the medical aesthetics segment where Dysport competes, and similar in scale and growth profile.
• Almirall: Spanish-headquartered specialty pharmaceutical company with European focus on dermatology and specialty care. Comparable in size and specialty pharma model; relevant for assessing Ipsen's European commercial execution.
• Leo Pharma: Danish specialty pharmaceutical company focused on dermatology and rare disease. Comparable mid-cap European specialty pharma with similar therapeutic-area breadth and specialty-pharmacy distribution model.
• UCB: Belgian specialty biopharma with a strong neurology and rare disease pipeline. Comparable to Ipsen in scale, European base, and emphasis on specialty therapeutics with global commercial reach.
• Lundbeck: Danish specialty pharmaceutical company focused on neuroscience, including spasticity and rare neurological conditions. Directly overlaps with Ipsen's neuroscience franchise (Dysport, post-stroke spasticity) in size, therapeutic focus, and European specialty pharma positioning.
• Recordati: Italian mid-cap specialty pharmaceutical company with a similar therapeutic focus (including rare diseases and specialty oncology) and comparable European commercial footprint. Closely matches Ipsen on size, geographic mix, and specialty pharma business model.

Broad incumbents

• AbbVie: Global biopharmaceutical major whose Botox franchise is the principal Dysport competitor across both spasticity and aesthetics. A relevant broad incumbent for benchmarking commercial scale and competitive dynamics in Ipsen's core neuroscience business.
• Sanofi: French-headquartered global biopharmaceutical major with a significant rare disease and specialty care portfolio. Comparable broad incumbent for Ipsen in terms of European HQ, payer access, and rare-disease strategy.
• Novartis: Global biopharmaceutical leader holding 21% of the neuroendocrine tumors treatment market versus Ipsen's 17%. Comparable broad incumbent for assessing Ipsen's oncology franchise positioning and pipeline scale.
• Takeda Pharmaceutical: Global biopharmaceutical company with a leading rare disease franchise (built largely through the Shire acquisition). Broad incumbent for benchmarking Ipsen's rare-disease strategy, geographic reach, and pipeline depth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/IpsenBiopharmaceutical
• Facebookfacebook.com/Ipsengroup
• LinkedInlinkedin.com/company/ipsen
• Instagraminstagram.com/ipsengroup

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ipsen Pharma SA